NCT02775240View on ClinicalTrials.gov

Study of SHP620 (Maribavir) in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

July 21, 2016

Primary Completion Date

September 12, 2016

Study Completion Date

September 12, 2016

Conditions

Cytomegalovirus (CMV)

Interventions

DRUG

Digoxin

0.5 mg (2 x 0.25 mg) Digoxin oral dose

DRUG

Maribavir

200mg twice a day for 8 days

DRUG

Dextromethorphan

30 mg oral dose

Trial Locations (1)

33014

Clinical Pharmacology of Miami, Inc., Miami

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Shire

INDUSTRY